Therapeutic doses of glucocorticoids are thought to inhibit prostaglandin and leukotriene formation in humans. Several studies in animals, however, have failed to demonstrate modulation of eicosanoid biosynthesis by steroids in vivo. We administered prednisone (60 mg/day) to eight healthy volunteers and measured eicosanoid formation by a variety of cell types in vivo and ex vivo, using sensitive and specific physicochemical assays. We found that the in vivo course of prednisone failed to inhibit the synthesis of thromboxane A2, prostaglandin 12 (prostacyclin), prostaglanin E2, and leukotriene E4 in vivo and of leukotriene B4 ex vivo. Biosynthesis of leukotriene B4, thromboxane B2, and prostaglandins F2 and E2 by macrophage-rich bronchoalveolar lavage cells was strongly suppressed. These findings indicate that therapeutic regimens of glucocorticoids suppress eicosanoid biosynthesis in human macrophages but not in a number of other cell types with steroid receptors, the capacity for eicosanoid formation, and lipocortin-like material. Study Design. In the 7-day study, the eight subjects took 60 mg of prednisone every morning by mouth for 7 days, the equivalent of 8 times the normal total daily production of hydrocortisone. On both of the 2 days immediately before drug treatment and again on both of the final 2 days of this course, heparinized (20 units/ml) whole blood and 24-hr urine collections were obtained. All blood samples were obtained at the same time of day, which at the end of the study was 2 hr after the preceding dose of prednisone. In four of these eight subjects, bronchoalveolar lavage was also performed, initially 1 week before the start and again at the end of the treatment. In the short-term study, the six subjects took 60 mg of prednisone by mouth at 0800 on two consecutive days. Twenty-four-hour urine collections were obtained before and on the first day of drug treatment and heparinized whole blood was obtained 0, 1, 2, 4, 8, 24 , and 30 hr after the first dose.
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Eicosanoids have potent proinflammatory actions in vitro and in vivo. For example, prostaglandins E and I (PGE2 and PGI2) are vasodilators and leukotriene B4 (LTB4) promotes chemotaxis and diapedesis (1) . Glucocorticoids are potent antiinflammatory drugs. Their biochemical mechanism of action, however, remains uncertain (2) . Early studies have demonstrated that steroids can suppress the formation of eicosanoids (3) and inhibit the release of arachidonic acid (4) in whole organ and cell culture systems. It has been hypothesized that steroids may act to inhibit the formation of eicosanoids in vivo and that this may contribute to their antiinflammatory effects.
Few studies have looked directly for a modulation of eicosanoid biosynthesis in response to steroid administration in vivo. Almost all have been performed in animals. These experiments, with rare exception (5) , have failed to demonstrate a suppressive effect (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , even in the face of unequivocal inhibition of eicosanoid formation in vitro (10) . We have designed a study to evaluate the effects of therapeutic doses of glucocorticoids on the synthesis of eicosanoids in vivo in humans.
METHODS
Subjects. Eight healthy volunteers (6 men, 2 women) aged [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] years participated in the 7-day study after giving informed consent. They were nonsmokers and had no history of asthma, allergy, or recent upper respiratory tract infection. They had no contraindications to steroid treatment and took no other medications before the study. Six similar subjects (4 men) participated in the short-term study. The investigation was approved by the Vanderbilt University Committee for the Protection of Human Subjects. Study Design. In the 7-day study, the eight subjects took 60 mg of prednisone every morning by mouth for 7 days, the equivalent of 8 times the normal total daily production of hydrocortisone. On both of the 2 days immediately before drug treatment and again on both of the final 2 days of this course, heparinized (20 units/ml) whole blood and 24-hr urine collections were obtained. All blood samples were obtained at the same time of day, which at the end of the study was 2 hr after the preceding dose of prednisone. In four of these eight subjects, bronchoalveolar lavage was also performed, initially 1 week before the start and again at the end of the treatment. In the short-term study, the six subjects took 60 mg of prednisone by mouth at 0800 on two consecutive days. Twenty-four-hour urine collections were obtained before and on the first day of drug treatment and heparinized whole blood was obtained 0, 1, 2, 4, 8, 24, and 30 hr after the first dose.
Plasma prednisone and prednisolone concentrations were measured by HPLC (16) . The completion of all urine collections obtained in the study was inferred from the close similarity of total creatinine in the four collections obtained from each subject. Prior to storage at -20°C, aliquots (5 ml) were equilibrated with stable-isotope-labeled standards.
Whole blood leukocyte stimulation ex vivo was performed as described (17) . Heparinized whole blood was divided into aliquots in polypropylene tubes and stimulants were added as follows: freshly opsonized zymosan A (100 and 250 ,ug/ml), the formylated tripeptide fMet-Leu-Phe (1 and 2 ,tM) in the presence of cytochalasin B (5 ttg/ml), anti-human IgE (1 and 2 ,g/ml), or no added stimulant (17) . After incubation at 37°C in a shaking water bath for 30 min, the plasma was immediately collected by centrifugation and aliquots were equilibrated with 5 ng of 2H4-labeled LTB4.
Bronchoscopy and Bronchoalveolar Lavage. Bronchoalveolar lavage cells (BALCs) were obtained as described (18 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
sonized zymosan A (100 ttg/ml) (19) . Incubation was continued with the stimulant for 4 hr. The culture media were then collected and centrifuged and the supernatants were equilibrated with eicosanoid standards for quantitative analysis.
Derivatization and Extraction of Elcosanoids. Urinary 2,3-dinorthromboxane B2 (2,3-dinor-TxB2) and 11-dehydro-TxB2 (20) , PGI-M (21), and PGE-M (22) and LTB4 released ex vivo (17) were analyzed by gas chromatography/mass spectrometry. Eicosanoids were measured in BALC supernatants by a modification of methods previously described (23) . Urinary LTE4 was measured by HPLC-RIA (18) .
RESULTS
Plasma Prednisone and Prednisolone. To confirm compliance with the protocol and demonstrate effective bioconversion of prednisone to its active form, prednisolone, we measured plasma prednisone and prednisolone on both ofthe 2 days before treatment and again on both of the final 2 days of treatment. The later samples were drawn 2 hr after ingestion of the daily dose of prednisone. Neither prednisone nor prednisolone was detectable in any subject on control days. Prednisone was again not detected on the final 2 days and prednisolone ranged from 340 to 650 ng/ml (mean + SD, 524 + 101).
Blood In BALCs obtained on control days, the spontaneous release of the three cyclooxygenase products increased linearly with increasing time in culture (Fig. 2, open bars) and maintained approximately constant relative proportions of 17:2.3:1 for TxB2/PGF2/PGE2. In contrast, LTB4 accumulation declined progressively with increasing time in culture. Stimulation by opsonized zymosan added for 4 hr after prestimulus culture times of 1.5, 4.5, or 7.5 hr (Fig. 3 , open bars) increased the release of the three cyclooxygenase products by 2-to 3-fold above the corresponding values for spontaneous release and again maintained their relative proportions unchanged. LTB4 accumulation after zymosan stimulation increased 3-to 4-fold above spontaneous release.
After prednisone administration in vivo, there was a profound reduction of eicosanoid release ex vivo by the BALCs. Release ofthe three cyclooxygenase products was reduced to only 12-19% of control values for zymosan-stimulated cells (Fig. 3, solid bars) . A very similar reduction, to 11-20% of control, occurred for spontaneous release (Fig. 2, solid bars) . In contrast, release of LTB4 was reduced only to 25% of control for zymosan-stimulated cells (Fig. 3, solid bars) and to 63% of control for unstimulated (spontaneous) release (Fig. 2, solid bars) . No measurable recovery from these degrees of inhibition occurred for any eicosanoid, even after 7.5 hr in culture before the addition of stimulant (Figs. 2 and  3, solid bars) .
In separate experiments conducted at the same time as the above, BALCs were exposed in vitro to hydrocortisone added to the wells during the incubation period that preceded the addition ofeither opsonized zymosan or buffer control. In BALCs obtained prior to prednisone administration (control BALCs), release of the three cyclooxygenase products showed a clear time-and concentration-dependent suppression for both zymosan-stimulated (Fig. 3, hatched bars) and spontaneous release (Fig. 2, hatched bars) . At the longest incubation time (7.5 hr plus 4 
DISCUSSION
We undertook this study to determine the effects of steroid treatment at antiinflammatory doses on eicosanoid formation in humans. The excretion of principal urinary metabolites of three eicosanoids was measured as an index of the daily systemic biosynthesis of their parent eicosanoids. Cyclooxygenase inhibitors dose-dependently inhibit excretion of these compounds (24) . This suggested that a similar suppression by steroid administration should have been readily detectable by this approach. Under physiologic conditions, urinary Tx-M derives principally from platelets (20) . Although glucocorticoids have been shown to inhibit TxA2 synthesis in U-937 cells (a monocyte-derived cell line) by a mechanism dependent upon steroid binding (25) , steroid receptors have not been reported in platelets, which lack a significant capacity for new protein synthesis. Thus, the lack of a prednisone effect on Tx-M is unsurprising and consistent with similar findings reported in patients in septic shock receiving intravenous steroids (11) . PG12 is a major product of endothelial cells in culture (26) and vascular stimulation results in marked augmentation of PGI-M excretion in vivo (27) . PGE2 is the predominant cyclooxygenase product of microvascular endothelial cells in culture (28) . Both PGI2 and PGE2 are formed at the site of vascular injury in humans (29) . Therefore, as endothelial cells have been reported to possess steroid receptors (30) and are susceptible to steroid inhibition of eicosanoid release in culture (31), the failure of steroid treatment to depress excretion of metabolites of these eicosanoids was unexpected. In fact, a small paradoxical increase was seen in PGE-M excretion, similar to findings reported in rabbits after dexamethasone treatment (9) . Excretion of LTE4 is increased coincident with allergen-evoked bronchospasm in allergic volunteers, and inhibition of LT formation has been speculated to contribute to the efficacy of steroids in the treatment of asthma (18) . In the short-term study, steroid administration did not alter LTE4 excretion in our healthy volunteers.
We chose an ex vivo whole blood model of stimulated leukocytes to assess the effect of in vivo administration of prednisone on the lipoxygenase pathway. In this model, leukocytes remain in the whole blood environment with drug concentrations closely approximating those present in vivo after therapeutic dosing. While the individual contributions by neutrophils and monocytes to total LTB4 release cannot be assessed, they are probably substantial (32) and dependent on the stimulus applied, for both monocytes (33) and neutrophils (34), whereas lymphocytes synthesize no LTB4 (32) . We found that after 1 week of treatment with prednisone, there was no reduction in stimulated LTB4 release. This was particularly surprising, because both neutrophils and monocytes participate in inflammatory reactions, bear steroid receptors (35) , and contain lipocortin-staining granules (36) (37) (38) . However, in a previous study of fractionated leukocytes, the prior administration of a single dose of dexamethasone has also been reported to have no effect on stimulated LTB4 release (14) . In the short-term study we demonstrated that coincident with the acute prednisone-induced leukocytosis, neutrophilia, and monocytopenia after 4-8 hr, there was actually a marked enhancement of the LTB4 released per leukocyte. Our whole blood model precludes the ability to discriminate selective effects on individual types of leukocytes. However, the increased LTB4 in the face of marked monocytopenia encouraged us to examine an alternative calculation of our data as if all LTB4 were derived from the neutrophil fraction. The results of this speculation suggest that LTB4 release per neutrophil may be increased to 1.5-to 2.5-fold above baseline 4-8 hr after steroid ingestion, whereas it is diminished to -50% after 7 days.
In contrast to these observations, we observed a simultaneous profound inhibition of eicosanoid release by BALCs. Both cyclooxygenase and lipoxygenase products were reduced, though somewhat unequally. In control BALCs, obtained before prednisone administration, the released amounts of the four eicosanoids were consistent with those previously reported for human alveolar macrophages (39) and LTB4 release per cell was substantially greater than that from blood leukocytes measured simultaneously.
Hydrocortisone added to cultured BALCs obtained prior to prednisolone administration also suppressed eicosanoid formation in a time-and dose-dependent fashion. However, even the longest drug incubation that we employed (7.5 hr) did not match the profound effect of the week-long course of prednisone on eicosanoid formation by BALCs ex vivo. This was especially true for LTB4. The time to maximal effect of steroid suppression appears to be substantial. This is the case for cultured rat alveolar macrophages (18), but not rat peritoneal macrophages (40) . Once induced, suppression in our own study was also long-lasting. BALCs obtained during prednisone administration showed no measurable recovery after culture ex vivo as long as 7.5 hr.
Under all the conditions in macrophage-rich BALCs the three cyclooxygenase products always appeared in approximately constant proportions to one another, whereas the kinetics of LTB4 accumulation followed an independent course. Thus, a constant duration of stimulation by zymosan (4 hr) resulted in increasingly large accumulations of cyclooxygenase products when applied after increasing prestimulus times in culture, whereas the opposite was true for LTB4. Furthermore, we also found that the inhibitory effects of both prednisone in vivo and hydrocortisone in culture were significantly (P < 0.01) less on the stimulated formation of LTB4 (to 25 ± 1.2% control) than on the other three metabolites (to 16 ± 2.0% control). This is unlike findings reported for rat alveolar macrophages in culture (41) and rat gastric tissue in vivo (13) but similar to observations with human alveolar macrophages and murine macrophages in culture (42) . Stimulated fibroblast cyclooxygenase activity is inhibited by glucocorticoids (43 
